Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2020 | Jul. 22, 2020 | |
Entity Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2020 | |
Document Transition Report | false | |
Entity File Number | 0-15386 | |
Entity Registrant Name | CERNER CORPORATION | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 2800 Rockcreek Parkway | |
Entity Address, City or Town | North Kansas City, | |
Entity Address, State or Province | MO | |
Entity Tax Identification Number | 43-1196944 | |
Entity Address, Postal Zip Code | 64117 | |
City Area Code | 816 | |
Local Phone Number | 221-1024 | |
Title of 12(b) Security | Common Stock, $0.01 par value per share | |
Trading Symbol | CERN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 305,381,551 | |
Entity Central Index Key | 0000804753 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q2 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 28, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 269,895 | $ 441,843 |
Short-term investments | 171,123 | 99,931 |
Receivables, net | 1,183,988 | 1,139,595 |
Inventory | 18,525 | 23,182 |
Prepaid Expense and Other Assets, Current | 410,016 | 392,073 |
Total current assets | 2,053,547 | 2,096,624 |
Property and equipment, net | 1,870,779 | 1,858,772 |
Right-of-use assets | 122,639 | 123,155 |
Software development costs, net | 973,060 | 939,859 |
Goodwill | 912,082 | 883,158 |
Intangible assets, net | 346,259 | 364,439 |
Long-term investments | 388,675 | 419,419 |
Other assets | 212,300 | 209,196 |
Total assets | 6,879,341 | 6,894,622 |
Current liabilities: | ||
Accounts payable | 261,540 | 273,440 |
Deferred revenue | 295,711 | 360,025 |
Accrued payroll and tax withholdings | 267,930 | 245,843 |
Other current liabilities | 181,621 | 148,140 |
Total current liabilities | 1,006,802 | 1,027,448 |
Long-term Debt | 1,338,467 | 1,038,382 |
Deferred income taxes | 381,926 | 377,657 |
Other liabilities | 134,130 | 133,807 |
Total liabilities | 2,861,325 | 2,577,294 |
Shareholders' Equity: | ||
Common stock, $0.01 par value, 500,000,000 shares authorized, 371,186,776 shares issued at June 30, 2020 and 367,634,796 shares issued at December 28, 2019 | 3,712 | 3,676 |
Additional paid-in capital | 2,120,341 | 1,905,171 |
Retained earnings | 6,101,402 | 5,934,909 |
Treasury stock, 65,919,144 shares at June 30, 2020 and 56,723,546 shares at December 28, 2019 | (4,057,768) | (3,407,768) |
Accumulated other comprehensive loss, net | (149,671) | (118,660) |
Total shareholders' equity | 4,018,016 | 4,317,328 |
Total liabilities and shareholders' equity | $ 6,879,341 | $ 6,894,622 |
Common stock, par value | $ 0.01 | |
Common Stock, Shares Authorized | 500,000,000 | |
Common stock, shares issued | 371,186,776 | 367,634,796 |
Treasury Stock, Shares | 65,919,144 | 56,723,546 |
Consolidated Statements Of Oper
Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Revenues | $ 1,330,349 | $ 1,431,061 | $ 2,742,090 | $ 2,820,938 |
Costs and expenses: | ||||
Cost of Goods and Services Sold | 211,963 | 268,673 | 466,379 | 521,877 |
Sales and client service | 645,087 | 678,895 | 1,281,736 | 1,319,082 |
Software development (Includes amortization of $61,197 and $122,208 for the three and six months ended June 30, 2020, respectively; and $56,005 and $112,250 for the three and six months ended June 29, 2019, respectively) | 178,955 | 181,047 | 364,275 | 361,408 |
General and administrative | 134,332 | 149,788 | 274,184 | 245,984 |
Amortization of acquisition-related intangibles | 13,114 | 21,541 | 30,242 | 43,526 |
Total costs and expenses | 1,183,451 | 1,299,944 | 2,416,816 | 2,491,877 |
Operating earnings | 146,898 | 131,117 | 325,274 | 329,061 |
Other income, net | 24,632 | 23,006 | 30,227 | 31,438 |
Earnings before income taxes | 171,530 | 154,123 | 355,501 | 360,499 |
Income taxes | (36,782) | (27,154) | (73,594) | (67,311) |
Net earnings | $ 134,748 | $ 126,969 | $ 281,907 | $ 293,188 |
Basic earnings per share | $ 0.44 | $ 0.40 | $ 0.92 | $ 0.91 |
Diluted earnings per share | $ 0.44 | $ 0.39 | $ 0.91 | $ 0.90 |
Basic weighted average shares outstanding | 304,776 | 321,280 | 307,256 | 322,485 |
Diluted weighted average shares outstanding | 306,717 | 324,662 | 309,520 | 325,498 |
Software development, amortization | $ 61,197 | $ 56,005 | $ 122,208 | $ 112,250 |
Consolidated Statements Of Comp
Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] | ||||
Net earnings | $ 134,748 | $ 126,969 | $ 281,907 | $ 293,188 |
Foreign currency translation adjustment and other (net of taxes (benefit) of $(88) and $337 for the three and six months ended June 30, 2020; and $179 and $(4) for the three and six months ended June 29, 2019, respectively) | 9,197 | (100) | (11,349) | 2,221 |
Unrealized loss on cash flow hedge (net of tax benefit of $332 and $6,682 for the three and six months ended June 30, 2020; and $4,069 for both the three and six months ended June 29, 2019, respectively) | (1,007) | (12,370) | (20,315) | (12,370) |
Unrealized holding gain on available-for-sale investments (net of taxes of $494 and $215 for the three and six months ended June 30, 2020; and $71 and $281 for the three and six months ended June 29, 2019, respectively) | 1,502 | 216 | 653 | 853 |
Comprehensive income | 144,440 | 114,715 | 250,896 | 283,892 |
Foreign currency translation adjustment and other, taxes (benefit) | (88) | 179 | 337 | (4) |
Unrealized loss on cash flow hedge, taxes (benefit) | 332 | 6,682 | 4,069 | |
Change in net unrealized holding gain (loss) on available-for-sale investments, taxes (benefit) | $ 494 | $ 71 | $ 215 | $ 281 |
Consolidated Statements Of Cash
Consolidated Statements Of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2020 | Jun. 29, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net earnings | $ 281,907 | $ 293,188 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | ||
Depreciation and amortization | 343,941 | 336,486 |
Share-based compensation expense | 72,580 | 42,884 |
Provision for deferred income taxes | 12,884 | 15,154 |
Investment gains | (26,410) | (15,509) |
Changes in assets and liabilities: | ||
Receivables, net | (48,426) | (47,839) |
Inventory | 5,509 | 1,875 |
Prepaid expenses and other | (36,431) | (76,048) |
Accounts payable | (31,711) | 24,980 |
Accrued income taxes | 26,358 | (1,569) |
Deferred revenue | (66,137) | (78,090) |
Other accrued liabilities | 8,032 | 28,564 |
Net cash provided by operating activities | 542,096 | 524,076 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Capital purchases | (166,296) | (277,874) |
Capitalized software development costs | (151,393) | (144,902) |
Purchases of investments | (91,957) | (140,723) |
Sales and maturities of investments | 81,022 | 289,669 |
Purchase of other intangibles | (20,656) | (17,457) |
Payments to Acquire Businesses, Net of Cash Acquired | (35,766) | 0 |
Net cash used in investing activities | (385,046) | (291,287) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Long-term debt issuance | 300,000 | 600,000 |
Proceeds from exercise of stock options | 156,908 | 125,000 |
Payments to taxing authorities in connection with shares directly withheld from associates | (14,217) | (4,860) |
Treasury stock purchases | (650,000) | (620,542) |
Dividends paid | (111,101) | 0 |
Other financing activities | (4,159) | (4,450) |
Net cash provided by (used in) financing activities | (322,569) | 95,148 |
Effect of exchange rate changes on cash and cash equivalents | (6,429) | 861 |
Net increase (decrease) in cash and cash equivalents | (171,948) | 328,798 |
Cash and cash equivalents at beginning of period | 441,843 | 374,126 |
Cash and cash equivalents at end of period | $ 269,895 | $ 702,924 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity Statement - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment | Treasury Stock [Member] | AOCI Attributable to Parent [Member] |
Balance at Dec. 29, 2018 | $ 3,622 | $ 1,559,562 | $ 5,576,525 | $ (2,107,768) | $ (103,552) | ||
Common stock, shares issued at Dec. 29, 2018 | 362,213,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 7 | 11,716 | |||||
Exercise of stock options, shares | 706,000 | ||||||
Employee share-based compensation expense | 19,860 | ||||||
Other comprehensive income (loss) | 2,958 | ||||||
Net earnings | 166,219 | ||||||
Balance at Mar. 30, 2019 | $ 3,629 | 1,591,138 | 5,742,744 | (2,107,768) | (100,594) | ||
Common Stock, shares issued at Mar. 30, 2019 | 362,919,000 | ||||||
Balance at Dec. 29, 2018 | $ 3,622 | 1,559,562 | 5,576,525 | (2,107,768) | (103,552) | ||
Common stock, shares issued at Dec. 29, 2018 | 362,213,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Net earnings | $ 293,188 | ||||||
Balance at Jun. 29, 2019 | $ 3,647 | 1,722,207 | 5,812,031 | (2,707,768) | (112,848) | ||
Common Stock, shares issued at Jun. 29, 2019 | 364,696,000 | ||||||
Balance at Mar. 30, 2019 | $ 3,629 | 1,591,138 | 5,742,744 | (2,107,768) | (100,594) | ||
Common stock, shares issued at Mar. 30, 2019 | 362,919,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 18 | 108,045 | |||||
Exercise of stock options, shares | 1,777,000 | ||||||
Employee share-based compensation expense | 23,024 | ||||||
Treasury Stock, Value, Acquired, Cost Method | (600,000) | ||||||
Dividends, Cash | (57,682) | ||||||
Other comprehensive income (loss) | (12,254) | ||||||
Net earnings | 126,969 | 126,969 | |||||
Balance at Jun. 29, 2019 | $ 3,647 | 1,722,207 | 5,812,031 | (2,707,768) | (112,848) | ||
Common Stock, shares issued at Jun. 29, 2019 | 364,696,000 | ||||||
Balance at Dec. 28, 2019 | $ 4,317,328 | $ 3,676 | 1,905,171 | 5,934,909 | $ (4,606) | (3,407,768) | (118,660) |
Common stock, shares issued at Dec. 28, 2019 | 367,634,796 | 367,635,000 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 26 | 114,050 | |||||
Exercise of stock options, shares | 2,543,000 | ||||||
Employee share-based compensation expense | 35,031 | ||||||
Treasury Stock, Value, Acquired, Cost Method | (650,000) | ||||||
Dividends, Cash | (55,206) | ||||||
Other comprehensive income (loss) | (40,703) | ||||||
Net earnings | 147,159 | ||||||
Balance at Mar. 31, 2020 | $ 3,702 | 2,054,252 | 6,022,256 | (4,057,768) | (159,363) | ||
Common Stock, shares issued at Mar. 31, 2020 | 370,178,000 | ||||||
Balance at Dec. 28, 2019 | $ 4,317,328 | $ 3,676 | 1,905,171 | 5,934,909 | $ (4,606) | (3,407,768) | (118,660) |
Common stock, shares issued at Dec. 28, 2019 | 367,634,796 | 367,635,000 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Treasury Stock, Value, Acquired, Cost Method | $ 650,000 | ||||||
Net earnings | 281,907 | ||||||
Balance at Jun. 30, 2020 | $ 4,018,016 | $ 3,712 | 2,120,341 | 6,101,402 | (4,057,768) | (149,671) | |
Common Stock, shares issued at Jun. 30, 2020 | 371,186,776 | 371,187,000 | |||||
Balance at Mar. 31, 2020 | $ 3,702 | 2,054,252 | 6,022,256 | (4,057,768) | (159,363) | ||
Common stock, shares issued at Mar. 31, 2020 | 370,178,000 | ||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||
Exercise of stock options | $ 10 | 28,540 | |||||
Exercise of stock options, shares | 1,009,000 | ||||||
Employee share-based compensation expense | 37,549 | ||||||
Dividends, Cash | (55,602) | ||||||
Other comprehensive income (loss) | 9,692 | ||||||
Net earnings | $ 134,748 | 134,748 | |||||
Balance at Jun. 30, 2020 | $ 4,018,016 | $ 3,712 | $ 2,120,341 | $ 6,101,402 | $ (4,057,768) | $ (149,671) | |
Common Stock, shares issued at Jun. 30, 2020 | 371,186,776 | 371,187,000 |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 6 Months Ended |
Jun. 30, 2020 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | Supplemental Disclosures of Cash Flow Information Six Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $8,831 and $8,164, respectively) $ 16,572 $ 8,907 Income taxes, net of refunds 8,690 47,877 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 22,270 22,551 |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information details - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2020 | Jun. 29, 2019 | |
Supplemental Cash Flow Elements [Abstract] | ||
Interest Paid, Capitalized | $ 8,831 | $ 8,164 |
Interest Paid | 16,572 | 8,907 |
Income Taxes Paid, Net | 8,690 | 47,877 |
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | $ 22,270 | $ 22,551 |
Interim Statement Presentation
Interim Statement Presentation (Notes) | 6 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Interim Statement Presentation | Interim Statement Presentation Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Cerner Corporation ("Cerner," the "Company," "we," "us" or "our") without audit, pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K. In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year. The condensed consolidated financial statements were prepared using GAAP. These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Fiscal Period End Prior to fiscal year 2020, our second fiscal quarter ended on the Saturday closest to June 30. The second quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 182 days, respectively, and ended on June 29, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the second quarter and year-to-date periods for 2020 presented herein consisted of 91 days and 185 days, respectively, and ended on June 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on June 30, 2020 and June 29, 2019, unless otherwise noted. Supplemental Disclosures of Cash Flow Information Six Months Ended (In thousands) 2020 2019 Cash paid during the period for: Interest (including amounts capitalized of $8,831 and $8,164, respectively) $ 16,572 $ 8,907 Income taxes, net of refunds 8,690 47,877 Non-cash items: Lease liabilities recorded upon the commencement of operating leases 22,270 22,551 Accounting Pronouncements Adopted in 2020 Credit Losses on Financial Instruments. In the first quarter of 2020, we adopted new guidance regarding impairment assessment for certain financial assets. Refer to Notes (3) and (4) for further details. Collaborative Arrangements. In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 , which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Reference Rate Reform. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard. |
Revenue from Contracts with Cus
Revenue from Contracts with Customers (Notes) | 6 Months Ended |
Jun. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Revenue from Contract with Customer [Text Block] | Revenue Recognition Disaggregation of Revenue The following tables present revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 138,950 $ 13,212 $ 152,162 $ 181,061 $ 16,052 $ 197,113 Technology resale 36,376 5,741 42,117 54,851 5,884 60,735 Subscriptions 85,281 6,771 92,052 83,573 6,197 89,770 Professional services 409,848 51,234 461,082 429,910 55,397 485,307 Managed services 275,679 31,479 307,158 268,560 29,091 297,651 Support and maintenance 220,301 53,735 274,036 225,602 50,809 276,411 Reimbursed travel 1,778 (36) 1,742 22,555 1,519 24,074 Total revenues $ 1,168,213 $ 162,136 $ 1,330,349 $ 1,266,112 $ 164,949 $ 1,431,061 Six Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Licensed software $ 285,447 $ 24,747 $ 310,194 $ 321,506 $ 30,084 $ 351,590 Technology resale 80,825 12,779 93,604 104,009 12,266 116,275 Subscriptions 172,217 14,220 186,437 161,275 12,786 174,061 Professional services 862,632 109,796 972,428 867,139 108,607 975,746 Managed services 555,415 61,097 616,512 545,885 56,159 602,044 Support and maintenance 443,717 104,000 547,717 452,083 101,291 553,374 Reimbursed travel 14,375 823 15,198 45,045 2,803 47,848 Total revenues $ 2,414,628 $ 327,462 $ 2,742,090 $ 2,496,942 $ 323,996 $ 2,820,938 The following tables present our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,101,797 $ 151,456 $ 1,253,253 $ 1,124,513 $ 148,092 $ 1,272,605 Revenue recognized at a point in time 66,416 10,680 77,096 141,599 16,857 158,456 Total revenues $ 1,168,213 $ 162,136 $ 1,330,349 $ 1,266,112 $ 164,949 $ 1,431,061 Six Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Revenue recognized over time $ 2,267,312 $ 304,900 $ 2,572,212 $ 2,260,495 $ 290,303 $ 2,550,798 Revenue recognized at a point in time 147,316 22,562 169,878 236,447 33,693 270,140 Total revenues $ 2,414,628 $ 327,462 $ 2,742,090 $ 2,496,942 $ 323,996 $ 2,820,938 Transaction Price Allocated to Remaining Performance Obligations As of June 30, 2020, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $13.66 billion of which we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter. Contract Liabilities Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities. Such amounts are classified in our condensed consolidated balance sheets as deferred revenue. During the six months ended June 30, 2020, we recognized $236 million of revenues that were included in our contract liability balance at the beginning of such period. Significant Customers A certain customer within our Domestic segment comprised 17% and 12% of our consolidated revenues for the second quarters of 2020 and 2019, respectively; and 17% and 11% for the first six months of 2020 and 2019, respectively. Amounts due from this same customer comprised 11% of client receivables as of June 30, 2020. |
Receivables
Receivables | 6 Months Ended |
Jun. 30, 2020 | |
Receivables [Abstract] | |
Receivables | Receivables A summary of net receivables is as follows: (In thousands) June 30, 2020 December 28, 2019 Client receivables $ 1,328,187 $ 1,245,670 Less: Allowance for doubtful accounts 144,199 106,075 Total receivables, net $ 1,183,988 $ 1,139,595 A reconciliation of the beginning and ending amount of our allowance for doubtful accounts is as follows: (In thousands) Allowance for doubtful accounts - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 45,861 Deductions (12,343) Allowance for doubtful accounts - balance at June 30, 2020 $ 144,199 During the first six months of 2020 and 2019, we received total client cash collections of $2.66 billion and $2.74 billion, respectively. Expected Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) The cumulative effect adjustment is the result of providing an allowance on unbilled client receivables, for which we have an unconditional right to invoice and receive payment in the future. Our estimates of expected credit losses for client receivables at both December 29, 2019 and June 30, 2020, were primarily based on historical credit loss experience and adjustments for certain asset-specific risk characteristics (i.e. known client financial hardship or bankruptcy). Exposure to credit losses may increase if our clients are adversely affected by changes in healthcare laws, reimbursement or payor models; economic pressures or uncertainty associated with local or global economic recessions; disruption associated with the COVID-19 pandemic; or other client-specific factors. Although we have historically not experienced significant credit losses, it is possible that there could be an adverse impact from potential adjustments to the carrying amount of client receivables as clients' cash flows are impacted by the COVID-19 pandemic and related economic uncertainty, which may be material. |
Investments
Investments | 6 Months Ended |
Jun. 30, 2020 | |
Investments [Abstract] | |
Investments | Investments Available-for-sale investments at June 30, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 36,403 $ — $ — $ 36,403 Time deposits 58,407 — — 58,407 Total cash equivalents 94,810 — — 94,810 Short-term investments: Time deposits 21,445 — — 21,445 Commercial paper 10,000 12 (7) 10,005 Government and corporate bonds 98,598 560 (7) 99,151 Total short-term investments 130,043 572 (14) 130,601 Long-term investments: Government and corporate bonds 62,473 385 (10) 62,848 Total available-for-sale investments $ 287,326 $ 957 $ (24) $ 288,259 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981 We sold available-for-sale investments for proceeds of $5 million during the six months ended June 30, 2020, resulting in insignificant losses in the period. Other Investments At June 30, 2020 and December 28, 2019, we had investments in equity securities that do not have readily determinable fair values of $315 million and $314 million, respectively, accounted for in accordance with Accounting Standards Codification Topic ("ASC") 321, Investments-Equity Securities . Such investments are included in long-term investments in our condensed consolidated balance sheets. We did not record any changes in the measurement of such investments during the six months ended June 30, 2020 and June 29, 2019, respectively. At June 30, 2020 and December 28, 2019, we had investments in equity securities with readily determinable fair values of $41 million and $14 million, respectively, accounted for in accordance with ASC 321. Such investments are included in short-term investments in our condensed consolidated balance sheets. Changes in the measurement of such investments favorably impacted other income, net by $26 million for both the three and six months ended June 30, 2020. At June 30, 2020 and December 28, 2019, we had investments in equity securities reported under the equity method of accounting of $10 million and $9 million, respectively. Such investments are included in long-term investments in our condensed consolidated balance sheets. Impairment Assessment We adopted ASU 2016-13 in the first quarter of 2020, which made certain amendments to the model used to assess available-for-sale debt securities for impairment. Such guidance provides that an available-for-sale debt security is impaired if the fair value of the security is less than its amortized cost basis. A determination is made whether the decline in fair value below the amortized cost basis has resulted from a credit loss or other factors, such as market liquidity or changes in interest rates. Impairment related to credit losses is recognized in net earnings, whereas impairment related to other factors is recognized as a component of accumulated other comprehensive loss, net. During the six months ended June 30, 2020, we did not recognize any impairment on our available-for-sale debt securities through net earnings. |
Debt
Debt | 6 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Debt Disclosure | Long-term Debt The following is a summary of indebtedness outstanding: (In thousands) June 30, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 14,162 14,162 Total indebtedness 1,339,162 1,039,162 Less: debt issuance costs (695) (780) Long-term debt $ 1,338,467 $ 1,038,382 Credit Agreement As of June 30, 2020, the interest rate on revolving credit loans outstanding under our Credit Agreement was 0.98% based on LIBOR plus the applicable spread. We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06%. At June 30, 2020 and December 28, 2019, this swap was in a net liability position with an aggregate fair value of $44 million and $17 million, respectively; which is presented in our condensed consolidated balance sheets in other current liabilities . Series 2020-A Senior Notes In March 2020, we issued $300 million aggregate principal amount of 2.50% senior unsecured Series 2020-A notes (the "Series 2020-A Notes") due March 11, 2030, pursuant to the Master Note Agreement (the "2019 Shelf Agreement") we entered into in November 2019. Interest on the Series 2020-A Notes is payable semiannually on each March 11 and September 11, commencing September 11, 2020, and the principal balance is due at maturity. The Company may prepay at any time all, or any part of, the outstanding principal amount of the Series 2020-A Notes, subject to the payment of a make-whole amount. The Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: • Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. • Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. • Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at June 30, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 36,403 $ — $ — Time deposits Cash equivalents — 58,407 — Time deposits Short-term investments — 21,445 — Commercial paper Short-term investments — 10,005 — Government and corporate bonds Short-term investments — 99,151 — Government and corporate bonds Long-term investments — 62,848 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 — Our investments in equity securities with readily determinable fair values accounted for in accordance with ASC 321 are measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such arrangements is based on quoted prices in active markets, reduced by a percentage reflecting a discount for lack of marketability. Our interest rate swap agreement is measured and recorded at fair value on a recurring basis using a Level 2 valuation. The fair value of such agreement is based on the market standard methodology of netting the discounted expected future variable cash receipts and the discounted future fixed cash payments. The variable cash receipts are based on an expectation of future interest rates derived from observed market interest rate forward curves. Since these inputs are observable in active markets over the terms that the instrument is held, the derivative is classified as Level 2 in the hierarchy. We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. The fair value of our long-term debt at June 30, 2020 and December 28, 2019 was approximately $1.34 billion and $1.07 billion, respectively. The carrying amount of such debt at June 30, 2020 and December 28, 2019 was $1.33 billion and $1.03 billion, respectively. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income TaxesWe determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment. Our effective tax rate was 20.7% and 18.7% for the first six months of 2020 and 2019, respectively. The increase in the effective tax rate in the first six months of 2020 is primarily due to a decrease in net excess tax benefits recognized as a component of income tax expense in connection with the exercise of stock options and the vesting of restricted share and share unit awards. |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Jun. 30, 2020 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Earnings Per Share A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 134,748 304,776 $ 0.44 $ 126,969 321,280 $ 0.40 Effect of dilutive securities: Stock options, non-vested shares and share units — 1,941 — 3,382 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 134,748 306,717 $ 0.44 $ 126,969 324,662 $ 0.39 For the three months ended June 30, 2020 and June 29, 2019, options to purchase 6.0 million and 9.4 million shares of common stock at per share prices ranging from $52.32 to $76.49 and $53.30 to $73.40, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive. Six Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 281,907 307,256 $ 0.92 $ 293,188 322,485 $ 0.91 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,264 — 3,013 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 281,907 309,520 $ 0.91 $ 293,188 325,498 $ 0.90 |
Share-Based Compensation
Share-Based Compensation | 6 Months Ended |
Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Shareholders' Equity and Share-based Payments | Share-Based Compensation and Equity Stock Options Stock option activity for the six months ended June 30, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 2 73.01 Exercised (3,159) 49.65 Forfeited and expired (211) 61.40 Outstanding as of June 30, 2020 12,048 58.04 $ 127,611 5.88 Exercisable as of June 30, 2020 7,988 $ 56.55 $ 96,755 5.06 The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the six months ended June 30, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.5 % Fair value per option $ 17.53 As of June 30, 2020, there was $67 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 2.32 years. Non-vested Shares and Share Units Non-vested share and share unit activity for the six months ended June 30, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 1,969 69.44 Vested (591) 65.71 Forfeited (49) 66.62 Outstanding as of June 30, 2020 3,963 $ 67.28 As of June 30, 2020, there was $215 million of total unrecognized compensation cost related to non-vested share and share unit awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 2.32 years. Share-Based Compensation Cost The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended Six Months Ended (In thousands) 2020 2019 2020 2019 Stock option and non-vested share and share unit compensation expense $ 37,549 $ 23,024 $ 72,580 $ 42,884 Associate stock purchase plan expense 1,727 1,749 2,828 3,291 Amounts capitalized in software development costs, net of amortization (1,076) (41) (1,821) 146 Amounts charged against earnings, before income tax benefit $ 38,200 $ 24,732 $ 73,587 $ 46,321 Amount of related income tax benefit recognized in earnings $ 8,191 $ 4,357 $ 14,634 $ 8,558 Treasury Stock Under our current share repurchase program, which was initially approved by our Board of Directors in May 2017 and most recently amended in December 2019, the Company is authorized to repurchase up to $3.70 billion of shares of our common stock, excluding transaction costs. The repurchases are to be effectuated in the open market, by block purchase, in privately negotiated transactions, or through other transactions managed by broker-dealers. No time limit was set for the completion of the program. During the six months ended June 30, 2020, we repurchased 9.2 million shares for total consideration of $650 million under the program. The shares were recorded as treasury stock and accounted for under the cost method. No repurchased shares have been retired. As of June 30, 2020, $1.03 billion remains available for repurchase under the program. Dividends On May 21, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on July 17, 2020 to shareholders of record as of June 5, 2020. On March 19, 2020, our Board of Directors declared a cash dividend of $0.18 per share on our issued and outstanding common stock, which was paid on April 17, 2020 to shareholders of record as of April 3, 2020. In connection with the declaration of such dividends, our non-vested shares and share units are entitled to dividend equivalents, which will be payable to the holder subject to, and upon vesting of, the underlying awards. Our outstanding stock options are not entitled to dividend or dividend equivalents. At both June 30, 2020 and December 28, 2019, our condensed consolidated balance sheets included liabilities for dividends payable of $56 million, which are included in other current liabilities. Accumulated Other Comprehensive Loss, Net (AOCI) The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 (126,893) (31,886) (584) (159,363) Other comprehensive income (loss) before reclassifications 9,197 (3,205) 1,502 7,494 Amounts reclassified from AOCI — 2,198 — 2,198 Balance at June 30, 2020 $ (117,696) $ (32,893) $ 918 $ (149,671) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 (100,618) — 24 (100,594) Other comprehensive income (loss) before reclassifications (100) (12,223) 216 (12,107) Amounts reclassified from AOCI — (147) — (147) Balance at June 29, 2019 $ (100,718) $ (12,370) $ 240 $ (112,848) The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended Six Months Ended AOCI Component Location 2020 2019 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (2,798) $ 180 $ (4,170) $ 180 Income taxes 600 (33) 850 (33) Total amount reclassified, net of tax $ (2,198) $ 147 $ (3,320) $ 147 |
Contingencies
Contingencies | 6 Months Ended |
Jun. 30, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies Disclosure | Contingencies We accrue estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies ("ASC 450"). No less than quarterly, and as facts and circumstances change, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any one or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our business, results of operations, cash flows or financial condition. As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. We filed our response to Fujitsu's Counterclaim on May 1, 2020. We believe that Fujitsu's claims are without merit and will vigorously defend against them, and we continue to believe that we have valid and equitable grounds for recovery of the disputed client receivables; however, there can be no assurances as to the outcome of the dispute. As previously disclosed, we recorded a pre-tax charge of $45 million in the fourth quarter of 2018 to provide an allowance against the disputed client receivables reflecting the uncertainty in collection of such receivables and related litigation risk resulting from the conclusion of the non-binding alternative dispute resolution procedures, which occurred before we filed our request for arbitration. We have not concluded that a loss related to the new claims raised by Fujitsu in the Counterclaim is probable, nor have we accrued a liability related to these claims beyond the previously reported pre-tax charge recorded in the fourth quarter of 2018. Although we believe a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Counterclaim given that the dispute is in the early stages of the arbitration process. Arbitration is not currently expected to occur before 2022. Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. and NextGen prior to the acquisition of the assets of Siemens Health Services, Inc. by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. The terms of our agreements with our clients generally provide for limited indemnification of such clients against losses, expenses and liabilities arising from third party or other claims based on, among other things, alleged infringement by our solutions of an intellectual property right of third parties or damages caused by data privacy breaches or system interruptions. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include, as applicable, a right to replace or modify an infringing solution. For several reasons, including the lack of a sufficient number of prior indemnification claims relating to IP infringement, data privacy breaches or system interruptions, the inherent uncertainty stemming from such claims, and the lack of a monetary liability limit for such claims under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions. In addition to commitments and obligations in the ordinary course of business, we are involved in various other legal proceedings and claims that arise in the ordinary course of business, including for example, employment and client disputes and litigation alleging solution and implementation defects, personal injury, intellectual property infringement, violations of law, breaches of contract and warranties, and compliance audits by various government agencies. Many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages. At this time, we do not believe the range of potential losses under any claims to be material to our consolidated financial statements. |
Segment Reporting
Segment Reporting | 6 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Segment Reporting | Segment Reporting We have two operating segments, Domestic and International. Revenues are derived primarily from the sale of clinical, financial and administrative information solutions and services. The cost of revenues includes the cost of third-party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, expenses associated with our managed services business, marketing expenses, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, general and administrative expenses, certain organizational restructuring and other expense, share-based compensation expense, and certain amortization and depreciation. Performance of the segments is assessed at the operating earnings level by our chief operating decision maker, who is our Chief Executive Officer. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis. The following table presents a summary of our operating segments and other expense for the three and six months ended June 30, 2020 and June 29, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,168,213 $ 162,136 $ — $ 1,330,349 Costs of revenue 189,779 22,184 — 211,963 Operating expenses 587,674 57,413 326,401 971,488 Total costs and expenses 777,453 79,597 326,401 1,183,451 Operating earnings (loss) $ 390,760 $ 82,539 $ (326,401) $ 146,898 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,266,112 $ 164,949 $ — $ 1,431,061 Costs of revenue 243,926 24,747 — 268,673 Operating expenses 605,636 73,258 352,377 1,031,271 Total costs and expenses 849,562 98,005 352,377 1,299,944 Operating earnings (loss) $ 416,550 $ 66,944 $ (352,377) $ 131,117 (In thousands) Domestic International Other Total Six Months Ended 2020 Revenues $ 2,414,628 $ 327,462 $ — $ 2,742,090 Costs of revenue 418,346 48,033 — 466,379 Operating expenses 1,157,768 123,968 668,701 1,950,437 Total costs and expenses 1,576,114 172,001 668,701 2,416,816 Operating earnings (loss) $ 838,514 $ 155,461 $ (668,701) $ 325,274 (In thousands) Domestic International Other Total Six Months Ended 2019 Revenues $ 2,496,942 $ 323,996 $ — $ 2,820,938 Costs of revenue 472,485 49,392 — 521,877 Operating expenses 1,177,654 141,427 650,919 1,970,000 Total costs and expenses 1,650,139 190,819 650,919 2,491,877 Operating earnings (loss) $ 846,803 $ 133,177 $ (650,919) $ 329,061 |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent EventsOn July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA. We received cash consideration of $224 million, which is subject to post-closing adjustments for working capital and certain other adjustments. Amounts within our June 30, 2020 and December 28, 2019 condensed consolidated balance sheets related to the disposed business operations were not material to our condensed consolidated financial statements. |
Organization, Consolidation and
Organization, Consolidation and Presentation of Financial Statements (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | The condensed consolidated financial statements were prepared using GAAP |
Fiscal Period, Policy [Policy Text Block] | Prior to fiscal year 2020, our second fiscal quarter ended on the Saturday closest to June 30. The second quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 182 days, respectively, and ended on June 29, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the second quarter and year-to-date periods for 2020 presented herein consisted of 91 days and 185 days, respectively, and ended on June 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on June 30, 2020 and June 29, 2019, unless otherwise noted. |
Revenue from Contracts with C_2
Revenue from Contracts with Customers (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Revenue from Contract with Customer [Abstract] | |
Disaggregation of Revenue [Table Text Block] | Disaggregation of Revenue The following tables present revenues disaggregated by our business models: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Licensed software $ 138,950 $ 13,212 $ 152,162 $ 181,061 $ 16,052 $ 197,113 Technology resale 36,376 5,741 42,117 54,851 5,884 60,735 Subscriptions 85,281 6,771 92,052 83,573 6,197 89,770 Professional services 409,848 51,234 461,082 429,910 55,397 485,307 Managed services 275,679 31,479 307,158 268,560 29,091 297,651 Support and maintenance 220,301 53,735 274,036 225,602 50,809 276,411 Reimbursed travel 1,778 (36) 1,742 22,555 1,519 24,074 Total revenues $ 1,168,213 $ 162,136 $ 1,330,349 $ 1,266,112 $ 164,949 $ 1,431,061 Six Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Licensed software $ 285,447 $ 24,747 $ 310,194 $ 321,506 $ 30,084 $ 351,590 Technology resale 80,825 12,779 93,604 104,009 12,266 116,275 Subscriptions 172,217 14,220 186,437 161,275 12,786 174,061 Professional services 862,632 109,796 972,428 867,139 108,607 975,746 Managed services 555,415 61,097 616,512 545,885 56,159 602,044 Support and maintenance 443,717 104,000 547,717 452,083 101,291 553,374 Reimbursed travel 14,375 823 15,198 45,045 2,803 47,848 Total revenues $ 2,414,628 $ 327,462 $ 2,742,090 $ 2,496,942 $ 323,996 $ 2,820,938 The following tables present our revenues disaggregated by timing of revenue recognition: Three Months Ended 2020 2019 (In thousands) Domestic International Total Domestic International Total Revenue recognized over time $ 1,101,797 $ 151,456 $ 1,253,253 $ 1,124,513 $ 148,092 $ 1,272,605 Revenue recognized at a point in time 66,416 10,680 77,096 141,599 16,857 158,456 Total revenues $ 1,168,213 $ 162,136 $ 1,330,349 $ 1,266,112 $ 164,949 $ 1,431,061 Six Months Ended 2020 2019 (In thousands) Domestic Segment International Segment Total Domestic Segment International Segment Total Revenue recognized over time $ 2,267,312 $ 304,900 $ 2,572,212 $ 2,260,495 $ 290,303 $ 2,550,798 Revenue recognized at a point in time 147,316 22,562 169,878 236,447 33,693 270,140 Total revenues $ 2,414,628 $ 327,462 $ 2,742,090 $ 2,496,942 $ 323,996 $ 2,820,938 |
Receivables (Tables)
Receivables (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Receivables [Abstract] | |
Summary of Net Receivables | A summary of net receivables is as follows: (In thousands) June 30, 2020 December 28, 2019 Client receivables $ 1,328,187 $ 1,245,670 Less: Allowance for doubtful accounts 144,199 106,075 Total receivables, net $ 1,183,988 $ 1,139,595 |
Accounts Receivable, Allowance for Credit Loss | A reconciliation of the beginning and ending amount of our allowance for doubtful accounts is as follows: (In thousands) Allowance for doubtful accounts - balance at December 28, 2019 $ 106,075 Cumulative effect of accounting change (ASU 2016-13) 4,606 Additions charged to costs and expenses 45,861 Deductions (12,343) Allowance for doubtful accounts - balance at June 30, 2020 $ 144,199 |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] | A summary of such cumulative effect adjustment is as follows: (In thousands) Increase/(Decrease) Receivables, net $ (4,606) Retained earnings (4,606) |
Investments (Tables)
Investments (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Investments [Abstract] | |
Schedule of available-for-sale investments | Available-for-sale investments at June 30, 2020 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 36,403 $ — $ — $ 36,403 Time deposits 58,407 — — 58,407 Total cash equivalents 94,810 — — 94,810 Short-term investments: Time deposits 21,445 — — 21,445 Commercial paper 10,000 12 (7) 10,005 Government and corporate bonds 98,598 560 (7) 99,151 Total short-term investments 130,043 572 (14) 130,601 Long-term investments: Government and corporate bonds 62,473 385 (10) 62,848 Total available-for-sale investments $ 287,326 $ 957 $ (24) $ 288,259 Available-for-sale investments at December 28, 2019 were as follows: (In thousands) Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash equivalents: Money market funds $ 185,666 $ — $ — $ 185,666 Time deposits 64,286 — — 64,286 Total cash equivalents 249,952 — — 249,952 Short-term investments: Time deposits 2,506 — — 2,506 Government and corporate bonds 83,272 52 (11) 83,313 Total short-term investments 85,778 52 (11) 85,819 Long-term investments: Government and corporate bonds 96,186 91 (67) 96,210 Total available-for-sale investments $ 431,916 $ 143 $ (78) $ 431,981 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | The following is a summary of indebtedness outstanding: (In thousands) June 30, 2020 December 28, 2019 Credit agreement loans due May 5, 2024 $ 600,000 $ 600,000 Senior notes: Series 2020-A due March 11, 2030 300,000 — Series 2015-A due February 15, 2022 225,000 225,000 Series 2015-B due February 14, 2025 200,000 200,000 Other 14,162 14,162 Total indebtedness 1,339,162 1,039,162 Less: debt issuance costs (695) (780) Long-term debt $ 1,338,467 $ 1,038,382 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at June 30, 2020: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 36,403 $ — $ — Time deposits Cash equivalents — 58,407 — Time deposits Short-term investments — 21,445 — Commercial paper Short-term investments — 10,005 — Government and corporate bonds Short-term investments — 99,151 — Government and corporate bonds Long-term investments — 62,848 — The following table details our investments in available-for-sale debt securities measured and recorded at fair value on a recurring basis at December 28, 2019: (In thousands) Fair Value Measurements Using Description Balance Sheet Classification Level 1 Level 2 Level 3 Money market funds Cash equivalents $ 185,666 $ — $ — Time deposits Cash equivalents — 64,286 — Time deposits Short-term investments — 2,506 — Government and corporate bonds Short-term investments — 83,313 — Government and corporate bonds Long-term investments — 96,210 — |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2020 | Jun. 30, 2020 | |
Earnings Per Share [Abstract] | ||
Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share | A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows: Three Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 134,748 304,776 $ 0.44 $ 126,969 321,280 $ 0.40 Effect of dilutive securities: Stock options, non-vested shares and share units — 1,941 — 3,382 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 134,748 306,717 $ 0.44 $ 126,969 324,662 $ 0.39 | Six Months Ended 2020 2019 Earnings Shares Per-Share Earnings Shares Per-Share (In thousands, except per share data) (Numerator) (Denominator) Amount (Numerator) (Denominator) Amount Basic earnings per share: Income available to common shareholders $ 281,907 307,256 $ 0.92 $ 293,188 322,485 $ 0.91 Effect of dilutive securities: Stock options, non-vested shares and share units — 2,264 — 3,013 Diluted earnings per share: Income available to common shareholders including assumed conversions $ 281,907 309,520 $ 0.91 $ 293,188 325,498 $ 0.90 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule Of Stock Options Activity | Stock option activity for the six months ended June 30, 2020 was as follows: (In thousands, except per share and term data) Number of Weighted- Aggregate Weighted-Average Outstanding at beginning of year 15,416 $ 56.36 Granted 2 73.01 Exercised (3,159) 49.65 Forfeited and expired (211) 61.40 Outstanding as of June 30, 2020 12,048 58.04 $ 127,611 5.88 Exercisable as of June 30, 2020 7,988 $ 56.55 $ 96,755 5.06 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | The weighted-average assumptions used to estimate the fair value, under the Black-Scholes-Merton pricing model, of stock options granted during the six months ended June 30, 2020 were as follows: Expected volatility (%) 24.5 % Expected dividend rate (%) 1 % Expected term (yrs) 6 Risk-free rate (%) 1.5 % Fair value per option $ 17.53 |
Schedule of Share-based Compensation, Restricted Stock Activity | Non-vested share and share unit activity for the six months ended June 30, 2020 was as follows: (In thousands, except per share data) Number of Shares Weighted-Average Outstanding at beginning of year 2,634 $ 65.30 Granted 1,969 69.44 Vested (591) 65.71 Forfeited (49) 66.62 Outstanding as of June 30, 2020 3,963 $ 67.28 |
Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations | The following table presents total compensation expense recognized with respect to stock options, non-vested shares and share units, and our associate stock purchase plan: Three Months Ended Six Months Ended (In thousands) 2020 2019 2020 2019 Stock option and non-vested share and share unit compensation expense $ 37,549 $ 23,024 $ 72,580 $ 42,884 Associate stock purchase plan expense 1,727 1,749 2,828 3,291 Amounts capitalized in software development costs, net of amortization (1,076) (41) (1,821) 146 Amounts charged against earnings, before income tax benefit $ 38,200 $ 24,732 $ 73,587 $ 46,321 Amount of related income tax benefit recognized in earnings $ 8,191 $ 4,357 $ 14,634 $ 8,558 |
Schedule of Accumulated Other Comprehensive Income (Loss) | The components of AOCI, net of tax, were as follows: Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 28, 2019 $ (106,347) $ (12,578) $ 265 $ (118,660) Other comprehensive income (loss) before reclassifications (20,546) (20,430) (849) (41,825) Amounts reclassified from AOCI — 1,122 — 1,122 Balance at March 31, 2020 (126,893) (31,886) (584) (159,363) Other comprehensive income (loss) before reclassifications 9,197 (3,205) 1,502 7,494 Amounts reclassified from AOCI — 2,198 — 2,198 Balance at June 30, 2020 $ (117,696) $ (32,893) $ 918 $ (149,671) Foreign currency translation adjustment and other Unrealized loss on cash flow hedge Unrealized holding gain (loss) on available-for-sale investments Total (In thousands) Balance at December 29, 2018 $ (102,939) $ — $ (613) $ (103,552) Other comprehensive income (loss) before reclassifications 2,321 — 637 2,958 Amounts reclassified from AOCI — — — — Balance at March 30, 2019 (100,618) — 24 (100,594) Other comprehensive income (loss) before reclassifications (100) (12,223) 216 (12,107) Amounts reclassified from AOCI — (147) — (147) Balance at June 29, 2019 $ (100,718) $ (12,370) $ 240 $ (112,848) |
Reclassification out of Accumulated Other Comprehensive Income | The effects on net earnings of amounts reclassified from AOCI were as follows: (In thousands) Three Months Ended Six Months Ended AOCI Component Location 2020 2019 2020 2019 Unrealized loss on cash flow hedge Other income, net $ (2,798) $ 180 $ (4,170) $ 180 Income taxes 600 (33) 850 (33) Total amount reclassified, net of tax $ (2,198) $ 147 $ (3,320) $ 147 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Summary of the Operating Information | The following table presents a summary of our operating segments and other expense for the three and six months ended June 30, 2020 and June 29, 2019: (In thousands) Domestic International Other Total Three Months Ended 2020 Revenues $ 1,168,213 $ 162,136 $ — $ 1,330,349 Costs of revenue 189,779 22,184 — 211,963 Operating expenses 587,674 57,413 326,401 971,488 Total costs and expenses 777,453 79,597 326,401 1,183,451 Operating earnings (loss) $ 390,760 $ 82,539 $ (326,401) $ 146,898 (In thousands) Domestic International Other Total Three Months Ended 2019 Revenues $ 1,266,112 $ 164,949 $ — $ 1,431,061 Costs of revenue 243,926 24,747 — 268,673 Operating expenses 605,636 73,258 352,377 1,031,271 Total costs and expenses 849,562 98,005 352,377 1,299,944 Operating earnings (loss) $ 416,550 $ 66,944 $ (352,377) $ 131,117 (In thousands) Domestic International Other Total Six Months Ended 2020 Revenues $ 2,414,628 $ 327,462 $ — $ 2,742,090 Costs of revenue 418,346 48,033 — 466,379 Operating expenses 1,157,768 123,968 668,701 1,950,437 Total costs and expenses 1,576,114 172,001 668,701 2,416,816 Operating earnings (loss) $ 838,514 $ 155,461 $ (668,701) $ 325,274 (In thousands) Domestic International Other Total Six Months Ended 2019 Revenues $ 2,496,942 $ 323,996 $ — $ 2,820,938 Costs of revenue 472,485 49,392 — 521,877 Operating expenses 1,177,654 141,427 650,919 1,970,000 Total costs and expenses 1,650,139 190,819 650,919 2,491,877 Operating earnings (loss) $ 846,803 $ 133,177 $ (650,919) $ 329,061 |
Policies (Details)
Policies (Details) | 6 Months Ended |
Jun. 30, 2020 | |
Interim Statement Presentation [Line Items] | |
Basis of Accounting, Policy [Policy Text Block] | The condensed consolidated financial statements were prepared using GAAP |
Use of Estimates, Policy [Policy Text Block] | These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses |
Fiscal Period, Policy [Policy Text Block] | Prior to fiscal year 2020, our second fiscal quarter ended on the Saturday closest to June 30. The second quarter and year-to-date periods for 2019 presented herein consisted of 91 days and 182 days, respectively, and ended on June 29, 2019. In December 2019, our Board of Directors approved the change of our fiscal year to a calendar year, commencing with fiscal year 2020. Accordingly, the second quarter and year-to-date periods for 2020 presented herein consisted of 91 days and 185 days, respectively, and ended on June 30, 2020. All references to periods in these notes to condensed consolidated financial statements represent the respective periods described above ending on June 30, 2020 and June 29, 2019, unless otherwise noted. |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional financial reporting alternatives to reduce the cost and complexity associated with the accounting for contracts and hedging relationships affected by reference rate reform, such as the upcoming discontinuance of the London Interbank Offered Rate ("LIBOR"). The accommodations within ASU 2020-04 may be applied prospectively from the beginning of our 2020 first quarter through December 31, 2022. We are currently evaluating the effect that ASU 2020-04 may have on our contracts that reference LIBOR, specifically, our Third Amended and Restated Credit Agreement (as amended, the "Credit Agreement") and related interest rate swap. As of the date of this filing, we have not elected to apply any of the provisions of this standard. |
Accounting Standards Update 2018-18 [Member] | |
Interim Statement Presentation [Line Items] | |
New Accounting Pronouncement or Change in Accounting Principle, Description | In November 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which clarifies when transactions between participants in a collaborative arrangement are within the scope of the FASB's recent revenue standard (Topic 606). Such guidance clarifies revenue recognition and financial statement presentation for transactions between collaboration participants. We adopted ASU 2018-18 in the first quarter of 2020. Such guidance did not have an impact on our consolidated financial statements and related disclosures. |
Disaggregation of Revenue (Deta
Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ 1,330,349 | $ 1,431,061 | $ 2,742,090 | $ 2,820,938 |
Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,253,253 | 1,272,605 | 2,572,212 | 2,550,798 |
Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 77,096 | 158,456 | 169,878 | 270,140 |
Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,168,213 | 1,266,112 | 2,414,628 | 2,496,942 |
Domestic Segment | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,101,797 | 1,124,513 | 2,267,312 | 2,260,495 |
Domestic Segment | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 66,416 | 141,599 | 147,316 | 236,447 |
International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 162,136 | 164,949 | 327,462 | 323,996 |
International Segment [Member] | Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 151,456 | 148,092 | 304,900 | 290,303 |
International Segment [Member] | Transferred at Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 10,680 | 16,857 | 22,562 | 33,693 |
Sales Revenue, Licensed Software, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 152,162 | 197,113 | 310,194 | 351,590 |
Sales Revenue, Licensed Software, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 138,950 | 181,061 | 285,447 | 321,506 |
Sales Revenue, Licensed Software, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 13,212 | 16,052 | 24,747 | 30,084 |
Sales Revenue, Technology Resale, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 42,117 | 60,735 | 93,604 | 116,275 |
Sales Revenue, Technology Resale, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 36,376 | 54,851 | 80,825 | 104,009 |
Sales Revenue, Technology Resale, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 5,741 | 5,884 | 12,779 | 12,266 |
Sales Revenue, Subscriptions, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 92,052 | 89,770 | 186,437 | 174,061 |
Sales Revenue, Subscriptions, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 85,281 | 83,573 | 172,217 | 161,275 |
Sales Revenue, Subscriptions, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 6,771 | 6,197 | 14,220 | 12,786 |
Sales Revenue, Professional Services, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 461,082 | 485,307 | 972,428 | 975,746 |
Sales Revenue, Professional Services, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 409,848 | 429,910 | 862,632 | 867,139 |
Sales Revenue, Professional Services, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 51,234 | 55,397 | 109,796 | 108,607 |
Sales Revenue, Managed Services, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 307,158 | 297,651 | 616,512 | 602,044 |
Sales Revenue, Managed Services, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 275,679 | 268,560 | 555,415 | 545,885 |
Sales Revenue, Managed Services, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 31,479 | 29,091 | 61,097 | 56,159 |
Sales Revenue, Support and Maintenance Services, Net [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 274,036 | 276,411 | 547,717 | 553,374 |
Sales Revenue, Support and Maintenance Services, Net [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 220,301 | 225,602 | 443,717 | 452,083 |
Sales Revenue, Support and Maintenance Services, Net [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 53,735 | 50,809 | 104,000 | 101,291 |
Sales Revenue, Reimbursement Revenue [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,742 | 24,074 | 15,198 | 47,848 |
Sales Revenue, Reimbursement Revenue [Member] | Domestic Segment | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,778 | 22,555 | 14,375 | 45,045 |
Sales Revenue, Reimbursement Revenue [Member] | International Segment [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ (36) | $ 1,519 | $ 823 | $ 2,803 |
Performance Obligation (Details
Performance Obligation (Details) $ in Millions | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Revenue Recognition [Line Items] | |
Revenue, Remaining Performance Obligation | $ 13,660 |
Contract with Customer, Liability, Revenue Recognized | $ 236 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation | we expect to recognize approximately 30% of the revenue over the next 12 months and the remainder thereafter |
Revenue from Contracts with C_3
Revenue from Contracts with Customers (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Revenue from Contract with Customer [Abstract] | ||||
Segment Reporting, Disclosure of Major Customers | 17 | 12 | 17 | 11 |
Credit Concentration Risk [Member] | ||||
Revenue from Contract with Customer [Abstract] | ||||
Concentration Risk, Percentage | 11.00% | |||
Concentration Risk [Line Items] | ||||
Concentration Risk, Percentage | 11.00% |
Receivables (Narrative) (Detail
Receivables (Narrative) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Jun. 29, 2019 | |
Receivables [Abstract] | ||
Client cash collections | $ 2,660 | $ 2,740 |
Accounting Standards Update 2016-13 [Member] | ||
Receivables [Abstract] | ||
New Accounting Pronouncement or Change in Accounting Principle, Description | In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
New Accounting Pronouncement or Change in Accounting Principle, Description | In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides a new impairment model for certain financial assets that is based on expected losses rather than incurred losses. Such guidance impacts how we determine our allowance for estimated uncollectible client receivables. The standard requires use of the modified retrospective (cumulative effect) transition approach as of the beginning of the first reporting period in which the guidance was effective, which for the Company was the first quarter of 2020. Under this transition method, the cumulative effect from prior periods upon applying this new guidance was recognized in our condensed consolidated balance sheets as of December 29, 2019. We did not recast comparative periods. |
Receivables (Summary Of Net Rec
Receivables (Summary Of Net Receivables) (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 28, 2019 |
Receivables [Abstract] | ||
Gross accounts receivable | $ 1,328,187 | $ 1,245,670 |
Less: Allowance for doubtful accounts | 144,199 | 106,075 |
Total receivables, net | $ 1,183,988 | $ 1,139,595 |
Schedule of Valuation and Quali
Schedule of Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2020 | Dec. 28, 2019 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||
Accounts Receivable, Credit Loss Expense (Reversal) | $ 45,861 | |
Accounts Receivable, Allowance for Credit Loss, Writeoff | (12,343) | |
Accounts Receivable, Allowance for Credit Loss | 144,199 | $ 106,075 |
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment | ||
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | ||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment | $ 4,606 |
Cumulative Effect Transition (D
Cumulative Effect Transition (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 28, 2019 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Retained Earnings | $ 6,101,402 | $ 5,934,909 |
Receivables, Net | $ 1,183,988 | 1,139,595 |
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Retained Earnings | (4,606) | |
Receivables, Net | $ (4,606) |
Investments (Narrative) (Detail
Investments (Narrative) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Dec. 28, 2019 | |
Investments [Abstract] | ||
Proceeds from Sale of Available-for-sale Securities | $ 5 | |
Equity Securities without Readily Determinable Fair Value, Amount | 315 | $ 314 |
Equity Securities, FV-NI | 41 | 14 |
Equity Securities, FV-NI, Unrealized Gain | 26 | |
Equity Method Investments | $ 10 | $ 9 |
Investments (Details)
Investments (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 28, 2019 |
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | $ 287,326 | $ 431,916 |
Gross Unrealized Gains | 957 | 143 |
Gross Unrealized Losses | (24) | (78) |
Debt Securities, Available-for-sale | 288,259 | 431,981 |
Cash equivalents [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 94,810 | 249,952 |
Debt Securities, Available-for-sale | 94,810 | 249,952 |
Cash equivalents [Member] | Money market funds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 36,403 | 185,666 |
Debt Securities, Available-for-sale | 36,403 | 185,666 |
Cash equivalents [Member] | Time deposits [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 58,407 | 64,286 |
Debt Securities, Available-for-sale | 58,407 | 64,286 |
Short-term investments [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 130,043 | 85,778 |
Gross Unrealized Gains | 572 | 52 |
Gross Unrealized Losses | (14) | (11) |
Debt Securities, Available-for-sale | 130,601 | 85,819 |
Short-term investments [Member] | Time deposits [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 21,445 | 2,506 |
Debt Securities, Available-for-sale | 21,445 | 2,506 |
Short-term investments [Member] | Commercial paper [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 10,000 | |
Gross Unrealized Gains | 12 | |
Gross Unrealized Losses | (7) | |
Debt Securities, Available-for-sale | 10,005 | |
Short-term investments [Member] | Government and corporate bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 98,598 | 83,272 |
Gross Unrealized Gains | 560 | 52 |
Gross Unrealized Losses | (7) | (11) |
Debt Securities, Available-for-sale | 99,151 | 83,313 |
Long-term investments [Member] | Government and corporate bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Adjusted Cost | 62,473 | 96,186 |
Gross Unrealized Gains | 385 | 91 |
Gross Unrealized Losses | (10) | (67) |
Debt Securities, Available-for-sale | $ 62,848 | $ 96,210 |
Schedule of Indebtedness Outsta
Schedule of Indebtedness Outstanding (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2020 | Dec. 28, 2019 | |
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 1,339,162 | $ 1,039,162 |
Debt Issuance Costs, Noncurrent, Net | 695 | 780 |
Long-term Debt | 1,338,467 | 1,038,382 |
Line of Credit | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 600,000 | 600,000 |
Debt Instrument, Maturity Date | May 5, 2024 | |
Senior Notes - Series 2020-A due March 11, 2030 | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 300,000 | 0 |
Debt Instrument, Maturity Date | Mar. 11, 2030 | |
Senior Notes - Series 2015 A due February 15, 2022 | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 225,000 | 225,000 |
Debt Instrument, Maturity Date | Feb. 15, 2022 | |
Senior Notes - Series 2015-B due February 14, 2025 | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 200,000 | 200,000 |
Debt Instrument, Maturity Date | Feb. 14, 2025 | |
Other | ||
Debt Instrument [Line Items] | ||
Carrying amount of long-term debt | $ 14,162 | $ 14,162 |
Indebtedness (Narrative) (Detai
Indebtedness (Narrative) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Dec. 28, 2019 | |
Debt Instrument [Line Items] | ||
Line of Credit Facility, Interest Rate at Period End | 0.98% | |
General Discussion of Derivative Instruments and Hedging Activities | We are exposed to market risk from fluctuations in the variable interest rates on outstanding indebtedness under our Credit Agreement. In order to manage this exposure, we have entered into an interest rate swap agreement to hedge the variability of cash flows associated with such interest obligations. The interest rate swap is designated as a cash flow hedge, which effectively fixes the interest rate on the hedged indebtedness under our Credit Agreement at 3.06% | |
Derivative, Fair Value, Net | $ 44 | $ 17 |
Debt Instrument, Amount Uncommitted and Available for Sale | 750 | |
Senior Notes - Series 2020-A due March 11, 2030 | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Face Amount | $ 300 | |
Debt Instrument, Interest Rate, Stated Percentage | 2.50% | |
Debt Instrument, Maturity Date | Mar. 11, 2030 | |
Debt Instrument, Frequency of Periodic Payment | payable semiannually | |
Debt Instrument, Date of First Required Payment | Sep. 11, 2020 | |
Debt Instrument, Restrictive Covenants | The Series 2020-A Notes are subject to the terms of the 2019 Shelf Agreement, which contains customary events of default and covenants related to limitations on indebtedness and transactions with affiliates and the maintenance of certain financial ratios. |
Fair Value Measurements (Narrat
Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2020 | Dec. 28, 2019 | |
Fair Value Disclosures [Abstract] | ||
Fair Value Measurements, Valuation Processes, Description | We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. We estimate the fair value of our long-term, variable rate debt using a Level 3 discounted cash flow analysis based on LIBOR rate forward curves. | |
Fair value of long-term debt, including current maturities | $ 1,340 | $ 1,070 |
Unsecured Long-term Debt, Noncurrent | $ 1,330 | $ 1,030 |
Fair Value Measurements Fair Va
Fair Value Measurements Fair Value, Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2020 | Dec. 28, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 288,259 | $ 431,981 |
Level 1 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 36,403 | 185,666 |
Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 58,407 | 64,286 |
Level 3 [Member] | Money market funds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | 0 |
Level 3 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and Cash Equivalents, Fair Value Disclosure | 0 | 0 |
Short-term investments [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 130,601 | 85,819 |
Short-term investments [Member] | Level 2 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 21,445 | 2,506 |
Short-term investments [Member] | Level 2 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 10,005 | |
Short-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 99,151 | 83,313 |
Short-term investments [Member] | Level 3 [Member] | Time deposits [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Short-term investments [Member] | Level 3 [Member] | Commercial paper [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | |
Short-term investments [Member] | Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 0 | 0 |
Long-term investments [Member] | Level 2 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | 62,848 | 96,210 |
Long-term investments [Member] | Level 3 [Member] | Government and corporate bonds [Member] | Fair Value, Measurements, Recurring [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt Securities, Available-for-sale | $ 0 | $ 0 |
Income Taxes (Details)
Income Taxes (Details) | 6 Months Ended | |
Jun. 30, 2020 | Jun. 29, 2019 | |
Income Tax Disclosure [Abstract] | ||
Effective tax rate | 20.70% | 18.70% |
Earnings Per Share (Reconciliat
Earnings Per Share (Reconciliation Of The Numerators And The Denominators Of The Basic And Diluted Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Earnings Per Share [Abstract] | ||||
Income available to common shareholders, basic | $ 134,748 | $ 126,969 | $ 281,907 | $ 293,188 |
Income available to common shareholders including assumed conversions, diluted | $ 134,748 | $ 126,969 | $ 281,907 | $ 293,188 |
Basic weighted average shares outstanding | 304,776 | 321,280 | 307,256 | 322,485 |
Stock options and non-vested shares, incremental shares | 1,941 | 3,382 | 2,264 | 3,013 |
Diluted weighted average shares outstanding | 306,717 | 324,662 | 309,520 | 325,498 |
Basic earnings per share | $ 0.44 | $ 0.40 | $ 0.92 | $ 0.91 |
Diluted earnings per share | $ 0.44 | $ 0.39 | $ 0.91 | $ 0.90 |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) - $ / shares shares in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Earnings Per Share [Abstract] | ||||
Antidilutive securities excluded from computation of earnings per share, amount | 6 | 9.4 | 4.5 | 12.5 |
Antidilutive securities excluded from computation of earnings per share, exercise price, lower range limit | $ 52.32 | $ 53.30 | $ 52.32 | $ 51.46 |
Antidilutive securities excluded from computation of earnings per share, exercise price, upper range limit | $ 76.49 | $ 73.40 | $ 76.49 | $ 73.40 |
Share-Based Compensation (Sched
Share-Based Compensation (Schedule Of Stock Options Activity) (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 6 Months Ended |
Jun. 30, 2020USD ($)$ / sharesshares | |
Share-based Payment Arrangement [Abstract] | |
Outstanding at beginning of year, number of shares | shares | 15,416 |
Outstanding at beginning of year, weighted-average exercise price | $ / shares | $ 56.36 |
Granted, number of shares | shares | 2 |
Granted, weighted-average exercise price | $ / shares | $ 73.01 |
Exercised, number of shares | shares | (3,159) |
Exercised, weighted-average exercise price | $ / shares | $ 49.65 |
Forfeited and expired, number of shares | shares | (211) |
Forfeited and expired, weighted-average exercise price | $ / shares | $ 61.40 |
Outstanding end of year, number of shares | shares | 12,048 |
Outstanding at end of year, weighted-average exercise price | $ / shares | $ 58.04 |
Outstanding at end of year, aggregate intrinsic value | $ | $ 127,611 |
Outstanding at end of year, weighted-average remaining contractual term | 5 years 10 months 17 days |
Exercisable at end of year, number of shares | shares | 7,988 |
Exercisable at end of year, weighted-average exercise price | $ / shares | $ 56.55 |
Exercisable at end of year, aggregate intrinsic value | $ | $ 96,755 |
Exercisable at end of year, weighted-average remaining contractual term | 5 years 21 days |
Share-Based Compensation (Sch_2
Share-Based Compensation (Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions) (Details) | 6 Months Ended |
Jun. 30, 2020$ / shares | |
Share-based Payment Arrangement [Abstract] | |
Expected volatility (%) | 24.50% |
Expected dividend rate | 1.00% |
Expected term (yrs) | 6 years |
Risk-free rate (%) | 1.50% |
Fair value per option | $ 17.53 |
Share-Based Compensation (Sch_3
Share-Based Compensation (Schedule Of Non-Vested Shares Activity) (Details) - Restricted Stock [Member] shares in Thousands | 6 Months Ended |
Jun. 30, 2020$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Outstanding at beginning of year, number of shares | shares | 2,634 |
Outstanding at beginning of year, weighted-average grant date fair value | $ / shares | $ 65.30 |
Granted, number of shares | shares | 1,969 |
Granted, weighted-average grant date fair value | $ / shares | $ 69.44 |
Vested, number of shares | shares | (591) |
Vested, weighted-average grant date fair value | $ / shares | $ 65.71 |
Forfeited, number of shares | shares | (49) |
Forfeited, weighted-average grant date fair value | $ / shares | $ 66.62 |
Outstanding at end of year, number of shares | shares | 3,963 |
Outstanding at end of year, weighted-average grant date fair value | $ / shares | $ 67.28 |
Share-Based Compensation (Compe
Share-Based Compensation (Compensation Expense Recognized In The Condensed Consolidated Statements Of Operations) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | $ 38,200 | $ 24,732 | $ 73,587 | $ 46,321 |
Amount of related income tax benefit recognized in earnings | 8,191 | 4,357 | 14,634 | 8,558 |
Stock option and non-vested share compensation expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | 37,549 | 23,024 | 72,580 | 42,884 |
Associate stock purchase plan expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | 1,727 | 1,749 | 2,828 | 3,291 |
Amounts capitalized in software development costs, net of amortization | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Amounts charged against earnings, before income tax benefit | $ (1,076) | $ (41) | $ (1,821) | $ 146 |
Schedule of Accumulated Other C
Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 3 Months Ended | |||||
Jun. 30, 2020 | Mar. 31, 2020 | Jun. 29, 2019 | Mar. 30, 2019 | Dec. 28, 2019 | Dec. 29, 2018 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Accumulated other comprehensive loss, net | $ (149,671) | $ (159,363) | $ (112,848) | $ (100,594) | $ (118,660) | $ (103,552) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 7,494 | (41,825) | (12,107) | 2,958 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 2,198 | 1,122 | (147) | 0 | ||
Accumulated Foreign Currency Adjustment Attributable to Parent | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Accumulated other comprehensive loss, net | (117,696) | (126,893) | (100,718) | (100,618) | (106,347) | (102,939) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 9,197 | (20,546) | (100) | 2,321 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 0 | 0 | 0 | 0 | ||
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Accumulated other comprehensive loss, net | (32,893) | (31,886) | (12,370) | 0 | (12,578) | 0 |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | (3,205) | (20,430) | (12,223) | 0 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | 2,198 | 1,122 | (147) | 0 | ||
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent | ||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||
Accumulated other comprehensive loss, net | 918 | (584) | 240 | 24 | $ 265 | $ (613) |
OCI, before Reclassifications, Net of Tax, Attributable to Parent | 1,502 | (849) | 216 | 637 | ||
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent | $ 0 | $ 0 | $ 0 | $ 0 |
Reclassification out of Accumul
Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | $ 24,632 | $ 23,006 | $ 30,227 | $ 31,438 |
Income Tax Expense (Benefit) | (36,782) | (27,154) | (73,594) | (67,311) |
Net earnings | 134,748 | 126,969 | 281,907 | 293,188 |
Reclassification out of Accumulated Other Comprehensive Income | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Net earnings | (2,198) | 147 | (3,320) | 147 |
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | ||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||
Other income, net | (2,798) | 180 | (4,170) | 180 |
Income Tax Expense (Benefit) | $ 600 | $ (33) | $ 850 | $ (33) |
Share-Based Compensation (Narra
Share-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options | $ 215 | $ 215 | |
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options | 67 | 67 | |
Stock Repurchase Program, Authorized Amount | 3,700 | 3,700 | |
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 1,030 | $ 1,030 | |
Dividends Payable, Date Declared | May 21, 2020 | Mar. 19, 2020 | |
Dividends Payable, Amount Per Share | $ 0.18 | $ 0.18 | $ 0.18 |
Dividends Payable, Date to be Paid | Jul. 17, 2020 | Apr. 17, 2020 | |
Dividends Payable, Date of Record | Jun. 5, 2020 | Apr. 3, 2020 | |
Dividends Payable | $ 56 | $ 56 | |
Treasury Stock, Value, Acquired, Cost Method | $ 650 | ||
Treasury Stock, Shares, Acquired | 9,200 | ||
Stock Options [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Period of recognition for remaining share-based compensation expense | 2 years 3 months 25 days | ||
Restricted Stock [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Period of recognition for remaining share-based compensation expense | 2 years 3 months 25 days |
Contingencies Contingencies (De
Contingencies Contingencies (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended |
Dec. 29, 2018 | Jun. 30, 2020 | |
Fujitsu [Member] | ||
Commitments and Contingencies Disclosure [Abstract] | ||
Loss Contingency, Management's Assessment and Process | As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. | |
Loss Contingencies [Line Items] | ||
Loss Contingency, Management's Assessment and Process | As previously disclosed, we continue to be in dispute with Fujitsu Services Limited ("Fujitsu") regarding Fujitsu's obligation to pay amounts to us due upon the termination of a subcontract, including client receivables, in connection with Fujitsu's contract as the prime contractor in the National Health Service ("NHS") initiative to automate clinical processes and digitize medical records in the Southern region of England. The NHS terminated its contract with Fujitsu, which gave rise to the termination of our subcontract with Fujitsu. We filed a request for arbitration with the London Court of International Arbitration on April 22, 2019 seeking damages. On December 30, 2019, Fujitsu filed its Defense and Counterclaim (the "Counterclaim") in response. In its Counterclaim, Fujitsu defends against our claim in full and argues that we are liable to Fujitsu for: (i) £306 million in damages based on our alleged fraudulent misrepresentations inducing Fujitsu to enter into the subcontract; or (ii) alternatively, £173.8 million in damages based on our alleged breaches of the subcontract. | |
Loss Contingency Accrual, Provision | $ 45 | |
NextGen [Member] | ||
Commitments and Contingencies Disclosure [Abstract] | ||
Loss Contingency, Management's Assessment and Process | Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. and NextGen prior to the acquisition of the assets of Siemens Health Services, Inc. by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. | |
Loss Contingencies [Line Items] | ||
Loss Contingency, Management's Assessment and Process | Cerner Health Services, Inc. ("Cerner HS"), a wholly owned subsidiary of Cerner Corporation, filed a lawsuit in the Chester County, Pennsylvania, Court of Common Pleas against NextGen Healthcare Information Systems, LLC ("NextGen") relating to a dispute arising out of a supplier relationship initially established between Siemens Health Services, Inc. and NextGen prior to the acquisition of the assets of Siemens Health Services, Inc. by Cerner HS in 2015. In September 2017, the court issued a preliminary injunction to prevent NextGen from refusing to honor certain contractual obligations to support Cerner HS's clients who use NextGen ambulatory EHR solutions. In September 2018, NextGen filed a counterclaim alleging breach of contract and tortious interference but did not specify its damages. In August 2019, NextGen provided an expert report alleging profit disgorgement damages of $135 million or, alternatively, $30.5 million in lost profit damages, but the report did not discuss how our actions allegedly caused NextGen's damages. In December 2019, we deposed NextGen's expert, gaining additional clarity on categories of alleged damages but not on the alleged theories of liability. A jury trial is set to begin on January 25, 2021. We believe NextGen's claims are without merit and will vigorously defend against them; however, there can be no assurances as to the outcome of the dispute. We have not concluded that a loss related to the claims raised by NextGen in its counterclaim is probable, nor have we accrued a liability related to these claims. Although a loss may be reasonably possible (as defined in ASC 450), we do not have sufficient information to determine the amount or range of reasonably possible loss in light of the inherent difficulty of predicting the outcome of litigation generally, the wide range of damages presented by NextGen's expert, and the continued lack of clarity on the causal connection between Cerner Corporation's and Cerner HS's actions and any alleged damages. |
Segment Reporting (Summary Of T
Segment Reporting (Summary Of The Operating Information) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 29, 2019 | Jun. 30, 2020 | Jun. 29, 2019 | |
Segment Reporting Information [Line Items] | ||||
Revenues | $ 1,330,349 | $ 1,431,061 | $ 2,742,090 | $ 2,820,938 |
Cost of revenues | 211,963 | 268,673 | 466,379 | 521,877 |
Operating expenses | 971,488 | 1,031,271 | 1,950,437 | 1,970,000 |
Total costs and expenses | 1,183,451 | 1,299,944 | 2,416,816 | 2,491,877 |
Operating earnings (loss) | 146,898 | 131,117 | 325,274 | 329,061 |
Domestic Segment | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 1,168,213 | 1,266,112 | 2,414,628 | 2,496,942 |
Cost of revenues | 189,779 | 243,926 | 418,346 | 472,485 |
Operating expenses | 587,674 | 605,636 | 1,157,768 | 1,177,654 |
Total costs and expenses | 777,453 | 849,562 | 1,576,114 | 1,650,139 |
Operating earnings (loss) | 390,760 | 416,550 | 838,514 | 846,803 |
International Segment [Member] | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 162,136 | 164,949 | 327,462 | 323,996 |
Cost of revenues | 22,184 | 24,747 | 48,033 | 49,392 |
Operating expenses | 57,413 | 73,258 | 123,968 | 141,427 |
Total costs and expenses | 79,597 | 98,005 | 172,001 | 190,819 |
Operating earnings (loss) | 82,539 | 66,944 | 155,461 | 133,177 |
Other | ||||
Segment Reporting Information [Line Items] | ||||
Operating expenses | 326,401 | 352,377 | 668,701 | 650,919 |
Total costs and expenses | 326,401 | 352,377 | 668,701 | 650,919 |
Operating earnings (loss) | $ (326,401) | $ (352,377) | $ (668,701) | $ (650,919) |
Subsequent Events (Details)
Subsequent Events (Details) - Subsequent Event [Member] $ in Millions | 3 Months Ended |
Sep. 30, 2020USD ($) | |
Subsequent Events [Abstract] | |
Proceeds from Divestiture of Businesses | $ 224 |
Subsequent Event, Description | On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA. |
Subsequent Event [Line Items] | |
Subsequent Event, Description | On July 1, 2020, we sold certain of our business operations, primarily conducted in Germany and Spain, to affiliates of CompuGroup Medical SE & Co. KGaA. |
Proceeds from Divestiture of Businesses | $ 224 |